secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-139510
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF
----------------------------------------------------------------------------

- Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
- Cash $12.0M at March 31, 2024; after May 2024 $20M offering, expects to fund operations into H2 2025.
- Positive Cohort 1 data for LTI-03 in IPF: statistically significant in 3 of 8 biomarkers; no SAEs reported.
- Topline results from high-dose Cohort 2 expected Q3 2024; also Brian Windsor appointed President and CEO in March.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/0001193125-24-139510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524139510/d825172d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-139510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer